Chromocell Therapeutics Net Income

As of the most recent data (June 2026), CHRO shows a net income of $-72M. That compares with $-9M in the prior-year period — down 691.7% year over year. That is below the sector sector average of $90M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CHRO's net income is now $-72M (was $-9M) — a 691.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Chromocell Therapeutics is outperforming or lagging.

The its sector sector average net income is about $90M. Chromocell Therapeutics is at $-72M, which is lower that average. That is roughly 179.3% below the sector mean. Use the comparison chart on this page to see how CHRO stacks up against individual peers as well.

Tracking CHRO's net income over time shows whether Chromocell Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-72M That compares with $-9M in the prior-year period — down 691.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net income page, Stockcircle has Chromocell Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-72M) with ownership activity and broader fundamentals.